Abbott, GSK Extend MAGE-A3 Companion Dx Collaboration into Skin Cancer
March 10, 2010
Abbott, GSK Extend MAGE-A3 Companion Dx Collaboration into Skin Cancer
GSK is conducting a Phase III study for a MAGE-A3-targeting therapeutic for the adjuvant treatment of melanoma. To receive the drug in the study, participants' tumors must be shown to express MAGE-A3 via a molecular test that Abbott is developing.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Abbott, GSK to Develop PCR-Based Molecular Dx to Select Patients for Trial Skin Cancer Therapy
March 4, 2010 / PCR Insider - GSK/Abbott Pen Rx/Dx Co-Development Deal for MAGE-A3 Non-Small Cell Lung Cancer Treatment
July 15, 2009 / Pharmacogenomics Reporter - FDA Official Says Personalized Medicine Regulation Taking Shape Following Zelboraf, Xalkori Success
February 1, 2012 / Pharmacogenomics Reporter - Abbott, GSK Add New Biomarker to Cancer Immunotherapy Companion Dx Agreement
December 1, 2011 / PCR Insider - Sanofi's Iniparib Fails Phase III Study, but Firm Investigating Benefit by Molecular Subtypes
June 15, 2011 / Pharmacogenomics Reporter